Investing.com - Mesoblast reported on Wednesday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.2195 on revenue of $1.92M. Analysts polled by Investing.com anticipated EPS of $-0.1 on revenue of $20.27M.
Mesoblast shares are down 11.19% from the beginning of the year and are trading at $7.54 , down-from-52-week-high.They are under-performing the Nasdaq which is up 6.74% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by Novo Nordisk ADR on Wednesday, May 5, 2021, who reported EPS of $0.8799 on revenue of $5.46B, compared to forecasts EPS of $0.8069 on revenue of $5.21B.
Medtronic had beat expectations on Thursday, May 27, 2021 with fourth quarter EPS of $1.5 on revenue of $8.19B, compared to forecast for EPS of $1.42 on revenue of $8.14B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar